Zhejiang Jiuzhou Pharmaceutical Future Growth

Future criteria checks 2/6

Zhejiang Jiuzhou Pharmaceutical is forecast to grow earnings and revenue by 16.4% and 14.7% per annum respectively. EPS is expected to grow by 16.4% per annum. Return on equity is forecast to be 14.9% in 3 years.

Key information

16.4%

Earnings growth rate

16.4%

EPS growth rate

Pharmaceuticals earnings growth	18.6%
Revenue growth rate	14.7%
Future return on equity	14.9%
Analyst coverage	Good
Last updated	29 Apr 2024

Recent future growth updates

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11

Recent updates

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Feb 28

Earnings and Revenue Growth Forecasts

SHSE:603456 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	7,954	1,556	N/A	2,010	4
12/31/2025	7,251	1,513	N/A	1,747	5
12/31/2024	6,294	1,259	N/A	1,574	5
3/31/2024	5,248	989	-185	767	N/A
12/31/2023	5,523	1,033	431	1,360	N/A
9/30/2023	5,649	1,145	311	1,135	N/A
6/30/2023	5,745	1,075	524	1,386	N/A
3/31/2023	5,823	994	518	1,300	N/A
12/31/2022	5,445	921	512	1,226	N/A
9/30/2022	5,432	904	787	1,490	N/A
6/30/2022	5,150	827	450	1,098	N/A
3/31/2022	4,581	747	448	1,050	N/A
12/31/2021	4,063	634	98	678	N/A
9/30/2021	3,906	614	-71	456	N/A
6/30/2021	3,507	526	115	494	N/A
3/31/2021	3,112	443	-59	330	N/A
12/31/2020	2,647	381	85	400	N/A
9/30/2020	2,404	341	308	612	N/A
6/30/2020	2,167	265	11	357	N/A
3/31/2020	2,010	227	206	529	N/A
12/31/2019	2,017	238	234	554	N/A
9/30/2019	1,952	198	43	357	N/A
6/30/2019	1,800	171	127	406	N/A
3/31/2019	1,785	149	114	363	N/A
12/31/2018	1,862	157	34	265	N/A
9/30/2018	1,752	128	186	325	N/A
6/30/2018	1,839	163	171	282	N/A
3/31/2018	1,798	157	98	215	N/A
12/31/2017	1,717	148	N/A	275	N/A
9/30/2017	1,696	139	N/A	157	N/A
6/30/2017	1,694	147	N/A	177	N/A
3/31/2017	1,697	116	N/A	85	N/A
12/31/2016	1,653	111	N/A	137	N/A
9/30/2016	1,559	118	N/A	83	N/A
6/30/2016	1,500	126	N/A	44	N/A
3/31/2016	1,458	197	N/A	73	N/A
12/31/2015	1,445	200	N/A	141	N/A
9/30/2015	1,432	195	N/A	110	N/A
6/30/2015	1,349	170	N/A	98	N/A
3/31/2015	1,325	142	N/A	184	N/A
12/31/2014	1,286	133	N/A	10	N/A
9/30/2014	1,229	155	N/A	138	N/A
12/31/2013	1,310	166	N/A	204	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603456's forecast earnings growth (16.4% per year) is above the savings rate (2.9%).

Earnings vs Market: 603456's earnings (16.4% per year) are forecast to grow slower than the CN market (24.2% per year).

High Growth Earnings: 603456's earnings are forecast to grow, but not significantly.

Revenue vs Market: 603456's revenue (14.7% per year) is forecast to grow faster than the CN market (14.7% per year).

High Growth Revenue: 603456's revenue (14.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603456's Return on Equity is forecast to be low in 3 years time (14.9%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Zhejiang Jiuzhou Pharmaceutical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Price target decreased by 13% to CN¥32.14

Price target decreased to CN¥50.46

Price target decreased to CN¥63.18

Price target increased to CN¥69.15

Price target raised to CN¥22.95

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.32 in 1Q 2023)

Now 21% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Price target decreased by 13% to CN¥32.14

Now 20% undervalued after recent price drop

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

Now 24% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Investor sentiment improves as stock rises 17%

Now 23% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 09, 2024

Third quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.31 in 2Q 2022)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2022)

Now 21% undervalued after recent price drop

Price target decreased to CN¥50.46

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.24 in 3Q 2021)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) announces an Equity Buyback for CNY 100 million worth of its shares.

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 2.5 billion in funding

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.22 in 2Q 2021)

Price target decreased to CN¥63.18

Less than half of directors are independent

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) signed Investment Agreement to acquire a 25.8% stake in Nan Jing Kang Chuan Ji Pharmatech Co., Ltd. from Yin Laisheng for CNY 40 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥69.15

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.14 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.04 in 1Q 2020)

New 90-day low: CN¥30.48

Investor sentiment deteriorated over the past week

New 90-day high: CN¥38.24

New 90-day high: CN¥35.97

New 90-day low: CN¥29.09

Third quarter earnings released

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q3, 2020 Results on Oct 22, 2020

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 1 billion in funding

Price target raised to CN¥22.95

First half earnings released

Earnings released

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies